Log In
Print
BCIQ
Print
Print this Print this
 

DPX-Survivac

  Manage Alerts
Collapse Summary General Information
Company Immunovaccine Inc.
DescriptionVaccine targeting survivin-expressing solid tumors using DepoVax delivery technology
Molecular Target Survivin (BIRC5)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationOvarian cancer
Indication DetailsPrevent ovarian cancer; Treat ovarian cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today